comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-27 18:53:38 - browse：6

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Stephen Quake on the Chan Zuckerberg quest to conquer disease

WSS

STAT Virtual Event: ASCO Recap, Live!

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Coercive sterilizations revealed by STAT prompt outrage

Medical device trials still don't enroll enough women, study finds

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

knowledge

comprehensive

explore

Cancer drug shortages should be causing more outrage

New report analyzes digital physical therapy solutions' effectiveness

Bright Health sells Medicare Advantage business to Molina

Cognito secures funding to test medical device for Alzheimer's

Anesthesiologist group: stop taking Ozempic before surgery

ARCH Venture Partners is raising $3 billion for a life sciences fund

Walensky prepares to leave CDC — and Congress — behind

Pharma companies must ensure equitable access to obesity drugs

Bright Health sells Medicare Advantage business to Molina

SAMSHA loosens regulations on methadone treatment centers

focus

New Ultima Genomics DNA sequencer can read genome for $100

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Cigna wins case to block Amy Bricker's move to CVS

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Juul spent big to court Black leaders to promote its e

focus

focus

hotspot

leisure time